Skip to main content

Featured

Gas Is Still $1.81 a Litre: Why Pump Prices Won't Fall (and What to Do Before Winter)

  Canadians hoping for relief at the pump got bad news heading into this week: it isn't coming soon. The national average for regular gas was $1.81 a litre on Friday, according to Kalibrate, with provincial averages ranging from $1.557 in Alberta to $2.156 in Newfoundland, per GasBuddy. That's after a big policy move. On Friday the G7 announced plans to release 100 million barrels of oil right away, starting with diesel. Brent crude dipped on the news, then climbed back to about US$102 a barrel by the afternoon. Don't expect the release to show up at your station, because crude is only half the story. Crude oil explains only half your pump price Wood Mackenzie's Jim Mitchell says crude makes up 50 to 60 per cent of the retail price of gas. The rest is the cost of refining it, and that's where the squeeze is. Bank of Canada Governor Tiff Macklem pointed to damaged refining capacity worldwide in a Sept. 21 speech, noting that pump prices reflect crude roughly US$40 a ...
Post a Comment
Read more

article

Labels

U.S. Drug Tariffs: A Looming Crisis for Global Supply Chains


The U.S. government's decision to impose tariffs on pharmaceutical imports has sent shockwaves through the healthcare industry, raising concerns about potential drug shortages and skyrocketing costs. Industry leaders warn that these tariffs could disrupt critical supply chains, affecting the availability of essential medications and medical devices.

Johnson & Johnson CEO Joaquin Duato has voiced concerns over the impact of these tariffs, advocating for tax incentives instead of trade barriers to support domestic drug manufacturing Warns Tariffs Could Disrupt U.S. Drug Supply Chains](https://www.theglobeandmail.com/investing/markets/stocks/LLY-N/pressreleases/31903548/jj-ceo-jnj-warns-tariffs-could-disrupt-us-drug-supply-chains/). Meanwhile, a recent survey indicates that healthcare executives anticipate significant price hikes, with some predicting an 18% increase in medical equipment costs and a 33% rise in critical device prices.

The American Hospital Association has urged the administration to reconsider these tariffs, emphasizing the reliance of U.S. healthcare providers on international sources for life-saving drugs and supplies. Experts caution that while the tariffs aim to boost domestic production, the transition could take years, leaving patients vulnerable to shortages and inflated prices.

As pharmaceutical companies scramble to adjust their supply chains, the industry faces an uncertain future. Whether these tariffs will achieve their intended goal or exacerbate existing challenges remains to be seen. Policymakers must weigh the long-term consequences carefully to ensure that patient care and affordability are not compromised.

Labels:

Comments

Post a Comment